120 related articles for article (PubMed ID: 31303386)
1. Synthesis and biological evaluation of novel benzo[c][1,2,5]thiadiazol-5-yl and thieno[3,2-c]- pyridin-2-yl imidazole derivatives as ALK5 inhibitors.
Guo Z; Song X; Zhao LM; Piao MG; Quan J; Piao HR; Jin CH
Bioorg Med Chem Lett; 2019 Aug; 29(16):2070-2075. PubMed ID: 31303386
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and antifibrosis evaluation of 4-(benzo-[c][1,2,5]thiadiazol-5-yl)-3(5)-(6-methyl- pyridin-2-yl)pyrazole and 3(5)-(6-methylpyridin- 2-yl)-4-(thieno-[3,2,-c]pyridin-2-yl)pyrazole derivatives.
Zhu WJ; Cui BW; Wang HM; Nan JX; Piao HR; Lian LH; Jin CH
Eur J Med Chem; 2019 Oct; 180():15-27. PubMed ID: 31299584
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of the epithelial-to- mesenchymal inhibitory activity of indazole-derived imidazoles as dual ALK5/p38α MAP inhibitors.
Liu YY; Guo Z; Wang JY; Wang HM; Da Qi J; Ma J; Piao HR; Jin CH; Jin X
Eur J Med Chem; 2021 Apr; 216():113311. PubMed ID: 33677350
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of 5-(fluoro-substituted-6-methylpyridin-2-yl)-4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)imidazoles as inhibitors of transforming growth factor-β type I receptor kinase.
Krishnaiah M; Jin CH; Sheen YY; Kim DK
Bioorg Med Chem Lett; 2015 Nov; 25(22):5228-31. PubMed ID: 26483198
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Evaluation of 3-Substituted-4-(quinoxalin-6-yl) Pyrazoles as TGF-β Type I Receptor Kinase Inhibitors.
Zhao LM; Guo Z; Xue YJ; Min JZ; Zhu WJ; Li XY; Piao HR; Jin CH
Molecules; 2018 Dec; 23(12):. PubMed ID: 30572609
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of amide derivatives containing the imidazole moiety and evaluation of their anti-cardiac fibrosis activity.
Yang YX; Guo J; Liu C; Nan JX; Wu YL; Jin CH
Arch Pharm (Weinheim); 2024 Apr; ():e2400131. PubMed ID: 38678538
[TBL] [Abstract][Full Text] [Related]
7. Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherapeutic/antifibrotic agent.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Rao KS; Lee HJ; Park SJ; Park HJ; Lee K; Sheen YY; Kim DK
J Med Chem; 2014 May; 57(10):4213-38. PubMed ID: 24786585
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and evaluation of small molecule imidazo[2,1-b][1,3,4]thiadiazoles as inhibitors of transforming growth factor-β type-I receptor kinase (ALK5).
Patel HM; Sing B; Bhardwaj V; Palkar M; Shaikh MS; Rane R; Alwan WS; Gadad AK; Noolvi MN; Karpoormath R
Eur J Med Chem; 2015 Mar; 93():599-613. PubMed ID: 25234355
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of 4-(pyridine-4-oxy)-3-(tetrahydro-2H-pyran-4-yl)-pyrazole derivatives as novel, potent of ALK5 receptor inhibitors.
Wang Z; Zhang Y; Wang H; Wang X; Yu Z; Zhao L
Bioorg Med Chem Lett; 2022 Apr; 61():128552. PubMed ID: 35051574
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, biological evaluation and molecular modelling of 2,4-disubstituted-5-(6-alkylpyridin-2-yl)-1
Park MS; Park HJ; An YJ; Choi JH; Cha G; Lee HJ; Park SJ; Dewang PM; Kim DK
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):702-712. PubMed ID: 32164459
[TBL] [Abstract][Full Text] [Related]
11. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.
Park CY; Son JY; Jin CH; Nam JS; Kim DK; Sheen YY
Eur J Cancer; 2011 Nov; 47(17):2642-53. PubMed ID: 21852112
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological activity evaluation of novel 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl) oxy) pyridine-2-yl) amino derivatives as potent transforming growth factor-β (TGF-β) type I receptor inhibitors.
Tan B; Zhang X; Quan X; Zheng G; Li X; Zhao L; Li W; Li B
Bioorg Med Chem Lett; 2020 Aug; 30(16):127339. PubMed ID: 32631540
[TBL] [Abstract][Full Text] [Related]
13. 4-([1,2,4]Triazolo[1,5-a]pyridin-6-yl)-5(3)-(6-methylpyridin-2-yl)imidazole and -pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type I receptor kinase.
Jin CH; Krishnaiah M; Sreenu D; Subrahmanyam VB; Park HJ; Park SJ; Sheen YY; Kim DK
Bioorg Med Chem; 2014 May; 22(9):2724-32. PubMed ID: 24704197
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles as inhibitors of transforming growth factor-β type I receptor (ALK5).
Guo C; Zhang C; Li X; Li W; Xu Z; Bao L; Ding Y; Wang L; Li S
Bioorg Med Chem Lett; 2013 Nov; 23(21):5850-4. PubMed ID: 24055046
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542.
Laping NJ; Grygielko E; Mathur A; Butter S; Bomberger J; Tweed C; Martin W; Fornwald J; Lehr R; Harling J; Gaster L; Callahan JF; Olson BA
Mol Pharmacol; 2002 Jul; 62(1):58-64. PubMed ID: 12065755
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Evaluation of Chiral Rhodanine Derivatives Bearing Quinoxalinyl Imidazole Moiety as ALK5 Inhibitors.
Zhao LM; Guo FY; Wang HM; Dou T; Da Qi J; Xu WB; Piao L; Jin X; Chen FE; Piao HR; Zheng CJ; Jin CH
Med Chem; 2022; 18(4):509-520. PubMed ID: 34182915
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-β type 1 receptor inhibitors.
Xu G; Zhang Y; Wang H; Guo Z; Wang X; Li X; Chang S; Sun T; Yu Z; Xu T; Zhao L; Wang Y; Yu W
Eur J Med Chem; 2020 Jul; 198():112354. PubMed ID: 32387837
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors.
Kim DK; Jang Y; Lee HS; Park HJ; Yoo J
J Med Chem; 2007 Jun; 50(13):3143-7. PubMed ID: 17552507
[TBL] [Abstract][Full Text] [Related]
19. 5-(1,3-Benzothiazol-6-yl)-4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazole derivatives as potent and selective transforming growth factor-β type I receptor inhibitors.
Amada H; Sekiguchi Y; Ono N; Koami T; Takayama T; Yabuuchi T; Katakai H; Ikeda A; Aoki M; Naruse T; Wada R; Nozoe A; Sato M
Bioorg Med Chem; 2012 Dec; 20(24):7128-38. PubMed ID: 23117174
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, Molecular Docking and Preliminary Antileukemic Activity of 4-Methoxybenzyl Derivatives Bearing Imidazo[2,1-b][1,3,4]thiadiazole.
Choodamani B; Cano Hernandez KG; Kumar S; Tony AM; Schiaffino Bustamante AY; Aguilera RJ; Schols D; Gopi Mohan C; Karki SS
Chem Biodivers; 2021 Feb; 18(2):e2000800. PubMed ID: 33274824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
